Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
6.01
Dollar change
-0.07
Percentage change
-1.15
%
Index- P/E- EPS (ttm)-5.13 Insider Own25.20% Shs Outstand10.52M Perf Week-9.90%
Market Cap67.13M Forward P/E- EPS next Y-2.09 Insider Trans0.00% Shs Float8.36M Perf Month-28.11%
Income-47.53M PEG- EPS next Q-0.60 Inst Own11.33% Short Float14.50% Perf Quarter-32.62%
Sales0.00M P/S- EPS this Y68.03% Inst Trans-3.05% Short Ratio2.18 Perf Half Y-34.53%
Book/sh-0.30 P/B- EPS next Y-5.06% ROA-284.97% Short Interest1.21M Perf Year-60.46%
Cash/sh0.28 P/C21.38 EPS next 5Y- ROE-566.49% 52W Range4.79 - 22.49 Perf YTD-67.86%
Dividend Est.- P/FCF- EPS past 5Y-126.41% ROI- 52W High-73.28% Beta1.75
Dividend TTM- Quick Ratio1.60 Sales past 5Y0.00% Gross Margin- 52W Low25.47% ATR (14)0.94
Dividend Ex-Date- Current Ratio1.60 EPS Y/Y TTM-43.77% Oper. Margin0.00% RSI (14)41.83 Volatility11.53% 12.10%
Employees6 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price40.20
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q91.55% Payout- Rel Volume0.24 Prev Close6.08
Sales Surprise- EPS Surprise11.82% Sales Q/Q- EarningsMay 13 BMO Avg Volume555.33K Price6.01
SMA20-15.11% SMA50-29.07% SMA200-37.80% Trades Volume131,696 Change-1.15%
Date Action Analyst Rating Change Price Target Change
Dec-29-23Initiated Canaccord Genuity Buy $36
Jul-07-21Reiterated Maxim Group Buy $45 → $150
Jun-11-24 08:00AM
Jun-05-24 08:00AM
May-28-24 09:55AM
May-21-24 07:30AM
May-13-24 01:53PM
07:30AM Loading…
07:30AM
May-09-24 07:30AM
May-06-24 07:30AM
Apr-30-24 10:17AM
Apr-29-24 02:54PM
12:12PM
10:51AM
10:20AM
10:10AM
Apr-24-24 09:55AM
09:55AM Loading…
Apr-08-24 09:55AM
Apr-02-24 12:53PM
07:30AM
Apr-01-24 08:00AM
Mar-21-24 09:55AM
Mar-20-24 07:30AM
Mar-18-24 08:52AM
Mar-06-24 03:33PM
Feb-27-24 08:00AM
Feb-26-24 01:14PM
Feb-14-24 07:30AM
Feb-12-24 04:06PM
Jan-30-24 08:00AM
Jan-24-24 08:00AM
Dec-21-23 04:13PM
01:00PM Loading…
Dec-11-23 01:00PM
Dec-05-23 07:30AM
Dec-01-23 11:12AM
07:30AM
Nov-27-23 07:30AM
Nov-08-23 05:00PM
Nov-02-23 07:30AM
Oct-31-23 08:00AM
Oct-30-23 04:48PM
04:42PM
Oct-24-23 09:13AM
Oct-18-23 08:30AM
Oct-16-23 10:47AM
Oct-13-23 12:42PM
Oct-12-23 11:29AM
11:10AM
08:02AM
Oct-11-23 09:24AM
Oct-10-23 10:24AM
Oct-09-23 09:49AM
08:52AM
Oct-06-23 12:03PM
07:30AM
Oct-04-23 11:39AM
09:32AM
09:27AM
Oct-03-23 10:45AM
09:43AM
09:11AM
Sep-29-23 12:32PM
Sep-25-23 12:06PM
12:04PM
Sep-22-23 12:00PM
11:57AM
07:57AM
Sep-21-23 01:23PM
09:35AM
Sep-20-23 10:45AM
Sep-19-23 08:30AM
Sep-18-23 01:15PM
11:39AM
Sep-13-23 11:03AM
Sep-12-23 11:56AM
11:49AM
Sep-11-23 02:43PM
Sep-07-23 12:58PM
11:28AM
07:57AM
Sep-06-23 10:31AM
07:46AM
Sep-04-23 12:14PM
Sep-01-23 02:38PM
01:27PM
Aug-30-23 11:51AM
Aug-29-23 11:32AM
Aug-28-23 11:42AM
11:38AM
Aug-24-23 11:50AM
Aug-22-23 10:26AM
09:39AM
Aug-15-23 07:20AM
Jul-28-23 12:56PM
Jul-18-23 08:18AM
Jun-27-23 07:30AM
Jun-20-23 12:05PM
Jun-08-23 07:30AM
May-11-23 07:00AM
May-04-23 09:55AM
Apr-27-23 07:00AM
Apr-25-23 11:36AM
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.